PARADIGM ‐HF Trial: Secondary Analyses Address Unanswered Questions

ConclusionsThe benefit of sacubitril/valsartan over enalapril for the primary endpoint in the PARADIGM‐HF trial is maintained throughout numerous secondary analyses. Though the subgroups analyzed are based on participants from a single clinical trial, clinicians can more confidently incorporate this novel therapy into practice with expanded knowledge of these existing analyses as well as ongoing prospective trials.This article is protected by copyright. All rights reserved.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - November 1, 2017 Category: Drugs & Pharmacology Authors: Kristin R. Smith, Chia ‐Chi Hsu, Theodore J. Berei, Ahmed Aldemerdash, Ian B. Hollis, Orly Vardeny, Jo Ellen Rodgers Tags: Review of Therapeutics Source Type: research